{
    "nct_id": "NCT05946213",
    "official_title": "The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer",
    "brief_title": "Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer",
    "cancer_type_display": "A study comparing shorter-duration stereotactic body radiation therapy (SBRT) to the usual radiation therapy for patients with high-risk prostate cancer.",
    "cancer_tags": [
      "Prostate Adenocarcinoma",
      "Stage III Prostate Cancer AJCC v8",
      "Stage IVA Prostate Cancer AJCC v8"
    ],
    "link_to_trial": "https://clinicaltrials.gov/study/NCT05946213",
    "phase": "Phase 3",
    "recruitment_status": "RECRUITING",
    "last_update_date": "2025-10-14",
    "enrollment": 1209,
    "min_age": 18,
    "max_age": null,
    "sex": "MALE",
    "is_metastatic_allowed": false,
    "performance_status_scale": "ECOG",
    "performance_status_values": [
      0,
      1,
      2
    ],
    "min_prior_lines": null,
    "max_prior_lines": null,
    "prior_treatments_required": null,
    "prior_treatments_excluded": [
      "Prior radiotherapy to the region of the study cancer",
      "Prior radical prostatectomy",
      "Prior ablative or focal therapy to the prostate"
    ],
    "principal_investigator": "Karen E Hoffman",
    "site_name": "University of Alabama at Birmingham Cancer Center",
    "contact_email": "tmyrick@uab.edu",
    "contact_phone": "205-934-0220",
    "locations": [
      {
        "facility": "University of Alabama at Birmingham Cancer Center",
        "status": "RECRUITING",
        "city": "Birmingham",
        "state": "Alabama",
        "zip": "35233",
        "country": "United States",
        "contacts": [
          {
            "name": "Site Public Contact",
            "role": "CONTACT",
            "phone": "205-934-0220",
            "email": "tmyrick@uab.edu"
          },
          {
            "name": "Andrew M. McDonald",
            "role": "PRINCIPAL_INVESTIGATOR"
          }
        ],
        "geoPoint": {
          "lat": 33.52066,
          "lon": -86.80249
        }
      }
    ],
    "key_inclusion_summary": [
      "Pathologically proven diagnosis of adenocarcinoma of the prostate.",
      "High-risk disease, defined as having at least one of the following: cT3a-T3b, PSA > 20 ng/mL, or Gleason Score of 8-10.",
      "No definitive clinical or radiologic evidence of metastatic disease outside of the pelvic nodes.",
      "Prostate gland volume less than 100 cc.",
      "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2."
    ],
    "key_exclusion_summary": [
      "Evidence of metastatic disease (M1a, M1b or M1c).",
      "Prior radiotherapy to the region of the study cancer.",
      "Prior radical prostatectomy.",
      "Prior ablative or focal therapy to the prostate.",
      "Contraindication to prostate MRI."
    ]
  }